Category: Business

MC2 Therapeutics Announces Positive Top-line Results from Phase 3 Clinical Trial Comparing MC2-01 Cream to Taclonex® in Adults with Psoriasis

by  •  • 0 Comments

COPENHAGEN, Denmark–(BUSINESS WIRE)–MC2 Therapeutics A/S, an emerging pharmaceutical company developing next generation patient-friendly topical therapies for skin and eye diseases, today announced the following top-line data from its US Phase 3 study (n=796) on the company’s investigational drug, MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%): Primary end-point MC2-01 Cream is superior to Taclonex® Topical Suspension (“Taclonex®”) at Week 8 based on treatment

Read more →

NIH Awards $6.5 Million to NDRI for Recovery of Human Tissues and Organs for Research

by  •  • 0 Comments

PHILADELPHIA–(BUSINESS WIRE)–The National Institutes of Health (NIH) have awarded $6,591,480 to the National Disease Research Interchange (NDRI) to support continued national leadership with the recovery and distribution of human organs and tissues for medical research. The five-year award of the Research Resource for Human Tissues and Organs (RRHTO) Cooperative Agreement funds NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program. Established in 1987, the HTORR Program provide

Read more →

Second Sight Completes $5.0 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

by  •  • 0 Comments

LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that it has entered into a stock purchase agreement effective August 14, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors, for the purchase of 3,225,807 shares of commo

Read more →

Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study

by  •  • 0 Comments

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced topline efficacy results from a double-masked, randomized, placebo-controlled study (AR-13324-CS206; NCT03233308) designed to evaluate the effect of Rhopressa® (netarsudil ophthalmi

Read more →

Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update

by  •  • 0 Comments

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “We had a busy and productive second quarter at Aerpio,” commented Stephen Hoffman, M.D. Ph.D., Chief Executive Officer of Aerpio. “Our ongoing TIME-2b study, evaluating the effect of AKB-9778, our first-in-class Tie2 acti

Read more →

STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement

by  •  • 0 Comments

MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, and Dr. Maro Kariya of Shinjuku LASIK Clinic in Tokyo, today announced they have entered into a multi-year Strategic Cooperation Agreement to provide STAAR’s EVO Visian ICL™ intraocular lenses as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refracti

Read more →